Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GRN | P28799 | 1/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL821308 | 0.85 | KDM4E (0.52) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL14043867 | 0.84 | TGFBR1 (0.39) | KDM4EGRNSORT1MAPTLMNA | |
| SCHEMBL26275310 | 0.81 | KDM4E (0.48) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL10221896 | 0.79 | KDM4E (0.47) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL255124 | 0.77 | SMN1; SMN2 (0.39) | KDM4EGRNSORT1LMNA | |
| SCHEMBL24415140 | 0.76 | GRN (0.44) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL20932926 | 0.76 | KDM4E (0.32) | KDM4EGRNSORT1 | |
| SCHEMBL17473204 | 0.75 | JAK2 (0.32) | KDM4EGRNSORT1MAPK14 | |
| SCHEMBL16441499 | 0.75 | JAK2 (0.36) | KDM4EGRNSORT1 | |
| SCHEMBL20932927 | 0.75 | MAP3K12 (0.44) | KDM4EGRNSORT1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2023-01-12 | — | — | US | disclosed |
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2021-09-28 | — | — | US | disclosed |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130731-B2 | Sulfonylureas and related compounds and use of same | NLRP3, PYCARD, IAPP | KDM4E 3179/4885GRN 2227/4885SORT1 1855/4885 |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | KDM4E 4550/4885GRN 1122/4885SORT1 490/4885 |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP4K2, MAP4K4 | KDM4E 1118/4885GRN 1669/4885SORT1 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.